Cohen & SteersNYSE: CNS

HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX. Details of the presentation are as follows: Title: Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs.

Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 Company strengthens cash position to extend runway to fund operations beyond data readout of Berubicin potentially pivotal GBM study Quarter marked by pipeline expansion with in-license of TPI 287, a late stage novel potential blood brain barrier permeable abeotaxane for treatment of brain malignancies HOUSTON, TX / ACCESSWIRE / November 15, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the third quarter 2024 ended September 30, 2024. "Our team has made nothing short of transformational advancements throughout 2024.

NEW YORK , Nov. 11, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $89.7 billion as of October 31, 2024, a decrease of $2.0 billion from assets under management of $91.8 billion at September 30, 2024. The decrease was due to market depreciation of $2.3 billion and distributions of $150 million, partially offset by net inflows of $454 million.

NEW YORK , Nov. 8, 2024 /PRNewswire/ -- Cohen & Steers, Inc.'s (NYSE: CNS) Board of Directors has appointed Karen Wilson Thissen as a director of the company. Ms. Thissen has also been appointed as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.

CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial will be presented as a poster presentation at the CNS Summit 2024, taking place November 10-13, in Boston, Massachusetts.

Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment. As part of the event, Professor Michael Weller, a leading Neuro-oncologist who currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals' potentially pivotal study of Berubicin, discussed the unmet need in glioblastoma multiforme (GBM), the current treatment landscape and the potential for Berubicin to provide a solution for this devasting disease.

HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been granted an exception until March 11, 2025, to regain compliance with the minimum bid price requirement in Listing Rule 5550(a)(2). About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

SAN FRANCISCO--(BUSINESS WIRE)--Elastic (NYSE: ESTC), the Search AI company, today announced its successful collaboration with LG CNS, a leading digital transformation company in Korea, to help transform the company's global knowledge management services with enhanced search for generative AI (GenAI). LG CNS's KeyLook AI search algorithm is a retrieval augmented generation (RAG) system developed at its in-house AI Center. The company has integrated Elasticsearch into its search algorithm, incre.

NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Cohen & Steers (NYSE: CNS) announced today that funds managed by the Private Real Estate Group of Cohen & Steers and the Investment Management business of Acadia Realty Trust (NYSE: AKR – "Acadia"), a publicly traded owner and operator of retail properties in the U.S., have entered into a joint venture to own The Walk at Highwoods, an open-air community shopping center in Tampa, Florida. The Walk at Highwoods is a 141,000 square foot power center located approximately 20 miles northeast of downtown Tampa in a high-growth suburban area.